Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Catalyst Biosciences announces special cash dividend of $1.43 per share » 16:07
09/01/22
09/01
16:07
09/01/22
16:07
CBIO

Catalyst Biosciences

$1.97 /

+0.015 (+0.77%)

Catalyst Biosciences…

Catalyst Biosciences announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the company's common stock previously disclosed by the ompany will be September 21. The dividend is payable on September 20 to stockholders of record at the close of business on September 6. Stockholders of record on the record date who sell their shares prior to the ex-dividend date will not receive the special dividend. The aggregate amount of the payment to be made in connection with this special dividend will be approximately $45M. The company anticipates that it may declare one or more additional special dividends in the future, although there can be no assurance that such distributions will occur or the timing of such distributions.

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$1.97 /

+0.015 (+0.77%)

CBIO Catalyst Biosciences
$1.97 /

+0.015 (+0.77%)

05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
03/31/22 Piper Sandler
Piper says 'stick it out' with Catalyst Biosciences exploring options
11/12/21 JonesTrading
Catalyst Biosciences downgraded to Hold from Buy at JonesTrading
11/12/21 Piper Sandler
Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler
CBIO Catalyst Biosciences
$1.97 /

+0.015 (+0.77%)

CBIO Catalyst Biosciences
$1.97 /

+0.015 (+0.77%)

CBIO Catalyst Biosciences
$1.97 /

+0.015 (+0.77%)

Hot Stocks
Catalyst Biosciences declares special cash dividend of $1.43 per share » 08:08
08/25/22
08/25
08:08
08/25/22
08:08
CBIO

Catalyst Biosciences

$1.99 /

+0.035 (+1.79%)

Catalyst Biosciences…

Catalyst Biosciences announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend will be approximately $45 million.

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$1.99 /

+0.035 (+1.79%)

CBIO Catalyst Biosciences
$1.99 /

+0.035 (+1.79%)

05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
03/31/22 Piper Sandler
Piper says 'stick it out' with Catalyst Biosciences exploring options
11/12/21 JonesTrading
Catalyst Biosciences downgraded to Hold from Buy at JonesTrading
11/12/21 Piper Sandler
Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler
CBIO Catalyst Biosciences
$1.99 /

+0.035 (+1.79%)

CBIO Catalyst Biosciences
$1.99 /

+0.035 (+1.79%)

CBIO Catalyst Biosciences
$1.99 /

+0.035 (+1.79%)

Hot Stocks
Catalyst Biosciences announces dismissal of JDS1 litigation » 08:04
08/19/22
08/19
08:04
08/19/22
08:04
CBIO

Catalyst Biosciences

$1.94 /

+0.02 (+1.04%)

Catalyst Biosciences…

Catalyst Biosciences announced that JDS1, one of the Company's stockholders, has dismissed its lawsuits against the Company. "With the JDS1 litigation behind us, the Board of Directors will be meeting to determine the details of an initial distribution of capital, and we will communicate this information to shareholders shortly," said Nassim Usman, Ph.D., CEO of Catalyst Biosciences. In addition to dismissing its lawsuits against the Company, JDS1 and certain of its affiliates have agreed to a customary standstill and voting commitment, and the parties have entered into mutual releases. The Company has agreed to reimburse JDS1 for some of its expenses. The agreement between the Company and JDS1 will be filed with the United States Securities and Exchange Commission. Details regarding the distribution of capital to stockholders, including the record date, distribution date and amount, will be announced once they have been determined by the Board. Stockholders do not need to take any action at this time.

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$1.94 /

+0.02 (+1.04%)

CBIO Catalyst Biosciences
$1.94 /

+0.02 (+1.04%)

05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
03/31/22 Piper Sandler
Piper says 'stick it out' with Catalyst Biosciences exploring options
11/12/21 JonesTrading
Catalyst Biosciences downgraded to Hold from Buy at JonesTrading
11/12/21 Piper Sandler
Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler
CBIO Catalyst Biosciences
$1.94 /

+0.02 (+1.04%)

CBIO Catalyst Biosciences
$1.94 /

+0.02 (+1.04%)

CBIO Catalyst Biosciences
$1.94 /

+0.02 (+1.04%)

Hot Stocks
Catalyst Biosciences announces withdrawal of JDS1 nominatons » 12:59
08/10/22
08/10
12:59
08/10/22
12:59
CBIO

Catalyst Biosciences

$1.86 /

+0.02 (+1.09%)

Catalyst Biosciences…

Catalyst Biosciences announced that it has received a notice from JDS1 that JDS1 has withdrawn the nominations of Shelly Lombard, Matthew Stecker, and Igor Volshteyn for election to the Catalyst Board of Directors at the Catalyst 2022 annual meeting of stockholders, which is scheduled for August 15, 2022. Accordingly, any votes cast for the Withdrawn Candidates will be disregarded at the 2022 Annual Meeting. JDS1 has not indicated whether it intends to submit votes cast by Catalyst stockholders on JDS1's gold proxy card with respect to the other matters on the agenda at the 2022 Annual Meeting.

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$1.86 /

+0.02 (+1.09%)

CBIO Catalyst Biosciences
$1.86 /

+0.02 (+1.09%)

05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
03/31/22 Piper Sandler
Piper says 'stick it out' with Catalyst Biosciences exploring options
11/12/21 JonesTrading
Catalyst Biosciences downgraded to Hold from Buy at JonesTrading
11/12/21 Piper Sandler
Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler
CBIO Catalyst Biosciences
$1.86 /

+0.02 (+1.09%)

CBIO Catalyst Biosciences
$1.86 /

+0.02 (+1.09%)

CBIO Catalyst Biosciences
$1.86 /

+0.02 (+1.09%)

Hot Stocks
Catalyst announces ISS, Glass Lewis recommend shareholders vote FOR nominees » 08:16
08/03/22
08/03
08:16
08/03/22
08:16
CBIO

Catalyst Biosciences

$1.77 /

+0.005 (+0.28%)

Catalyst Biosciences…

Catalyst Biosciences announced that leading proxy advisory firms Institutional Shareholder Services, ISS, and Glass Lewis have recommended that Catalyst stockholders vote FOR all of the Company's nominees on the WHITE proxy card in advance of Catalyst's upcoming 2022 Annual Meeting of Stockholders, scheduled to be held on August 15, 2022. In its report, ISS specifically noted: "In light of the board's success at selling the complement portfolio for more than the market's expectations, and its commitment to make an initial cash distribution to shareholders following the resolution of the dissident's proxy contest and litigation, shareholders appear to be best served by encouraging the board to continue pursuing its existing plan." In its report, Glass Lewis specifically noted: "Given that the board has already implemented the Dissident's core suggestions for the Company, we believe there is insufficient basis to support the Dissident's campaign for further board seats at this time." On behalf of the Board, Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences, commented, "We are pleased that both ISS and Glass Lewis have recommended that Catalyst stockholders support the reelection of our three nominees. Augustine Lawlor, Dr. Geoffrey Ling and Eddie Williams are highly qualified leaders, each of whom played an important role in developing our Cash Distribution Plan and is fully committed to implementing the Plan for the benefit of all stockholders."

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$1.77 /

+0.005 (+0.28%)

CBIO Catalyst Biosciences
$1.77 /

+0.005 (+0.28%)

05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
03/31/22 Piper Sandler
Piper says 'stick it out' with Catalyst Biosciences exploring options
11/12/21 JonesTrading
Catalyst Biosciences downgraded to Hold from Buy at JonesTrading
11/12/21 Piper Sandler
Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler
CBIO Catalyst Biosciences
$1.77 /

+0.005 (+0.28%)

CBIO Catalyst Biosciences
$1.77 /

+0.005 (+0.28%)

CBIO Catalyst Biosciences
$1.77 /

+0.005 (+0.28%)

Hot Stocks
Catalyst Biosciences urges shareholders to vote for Catalyst nominees » 08:41
08/01/22
08/01
08:41
08/01/22
08:41
CBIO

Catalyst Biosciences

$1.74 /

-0.025 (-1.42%)

Catalyst Biosciences…

Catalyst Biosciences published a detailed investor presentation in advance of its upcoming 2022 Annual Meeting of Stockholders, scheduled to be held on August 15, 2022. The company said, "The presentation highlights the current Board's commitment to returning all of its available cash to stockholders. It also reiterates the overall strength of the Catalyst Board of Directors and encourages Catalyst stockholders to reelect the Company's three highly qualified nominees by voting "FOR" ALL nominees on the WHITE proxy card. Key highlights from the presentation include: The Catalyst Board has taken decisive action to change the Company's strategy and maximize stockholder value. The Board initiated a comprehensive review of strategic alternatives, which resulted in the monetization of a portion of the Company's product portfolio for significant value. The Company then reduced operating expenses, shrunk the workforce to six employees, ceased all R&D, and sold lab equipment and other assets. The Board is committed to distributing all of the Company's available cash expeditiously to stockholders, after reserving for liabilities and obligations. The Company has committed to announcing a record date for a substantial distribution of cash to stockholders as soon as the litigation with JDS1 and the proxy contest are resolved. If the litigation and proxy contest are concluded soon and without much additional expense, the Company expects that initial distribution to be $45 million. The Company estimates that it may ultimately be able to provide stockholders up to $65 million in cash, in one or more distributions, and will continue to pursue the monetization of the Company's remaining assets, which may generate additional value. In addition, the Board appointed the Company's largest single stockholder1 as an observer to the Board's Transaction Committee to help oversee the management of this ongoing effort. JDS1 is effectively blocking the Cash Distribution Plan. The Catalyst Board cannot distribute cash to stockholders without first understanding the full extent of the Company's liabilities and obligations. The Company must reserve enough cash to satisfy its obligations. Unfortunately, JDS1, through its proxy contest and litigation, is creating uncertainty about our ongoing and future liabilities and obligations by, among other things, suing the Company for unspecified damages. We believe JDS1's actions are driven by its desire to control Catalyst's cash. JDS1 and the Singer family have a history of obtaining control or seeking to obtain control of cash-rich companies, then having those companies sign investment management contracts with Singer family entities. We are concerned, given the Singer family's track record at CCUR Holdings and Symbolic Logic, that JDS1 is seeking to gain control of Catalyst's cash for the benefit of the Singer family and associates. The Board and each of the Company's nominees were instrumental in developing our Cash Distribution Plan and are fully committed to implementing it. The Board is focused on distributing the Company's available cash as soon as practicable and will continue its efforts to monetize the Company's remaining assets. On the other hand, JDS1's nominees have no differentiated suggestions for improving Catalyst; they do, however, have numerous and longstanding ties to each other and the Singer family. Our Board has determined that the best way to maximize value for stockholders is to monetize the Company's assets and distribute available cash to stockholders. We encourage stockholders to support Catalyst's Board of Directors and the Cash Distribution Plan."

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$1.74 /

-0.025 (-1.42%)

CBIO Catalyst Biosciences
$1.74 /

-0.025 (-1.42%)

05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
03/31/22 Piper Sandler
Piper says 'stick it out' with Catalyst Biosciences exploring options
11/12/21 JonesTrading
Catalyst Biosciences downgraded to Hold from Buy at JonesTrading
11/12/21 Piper Sandler
Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler
CBIO Catalyst Biosciences
$1.74 /

-0.025 (-1.42%)

CBIO Catalyst Biosciences
$1.74 /

-0.025 (-1.42%)

CBIO Catalyst Biosciences
$1.74 /

-0.025 (-1.42%)

Hot Stocks
Catalyst Biosciences says JEC agrees to vote in favor of Catalyst's nominees » 07:38
08/01/22
08/01
07:38
08/01/22
07:38
CBIO

Catalyst Biosciences

$1.74 /

-0.025 (-1.42%)

Catalyst Biosciences…

Catalyst Biosciences announced that it has reached an agreement with its largest single stockholder, JEC II Associates, under which JEC has committed to vote all of the Catalyst shares over which it has voting authority in favor of Catalyst's nominees for the Board of Directors on the Company's WHITE proxy card at the Company's upcoming 2022 Annual Meeting of Stockholders, scheduled to be held on August 15, 2022. In addition, Michael Torok, the Managing Director of JEC, has been appointed as an observer to the Transaction Committee of the Company's Board of Directors, effective immediately. Separately, the Board has committed to distributing a significant portion of the Company's available cash to stockholders and announcing a record date for that distribution within five business days following the conclusion of the Company's Delaware litigation and proxy contest with JDS1, assuming that no other litigation arises beforehand. The company said, "If the litigation and proxy contest are concluded soon and without much additional expense, the Company expects that initial distribution to be $45 million. As the Company stated in a letter to stockholders on July 19, 2022, we estimate that we may ultimately provide stockholders up to $65 million in cash, in one or more distributions, and we continue to pursue the monetization of our remaining assets that may generate additional value. Catalyst urges other stockholders to join JEC in supporting the Cash Distribution Plan by voting "FOR" ALL nominees on the WHITE proxy card."

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$1.74 /

-0.025 (-1.42%)

CBIO Catalyst Biosciences
$1.74 /

-0.025 (-1.42%)

05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
03/31/22 Piper Sandler
Piper says 'stick it out' with Catalyst Biosciences exploring options
11/12/21 JonesTrading
Catalyst Biosciences downgraded to Hold from Buy at JonesTrading
11/12/21 Piper Sandler
Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler
CBIO Catalyst Biosciences
$1.74 /

-0.025 (-1.42%)

CBIO Catalyst Biosciences
$1.74 /

-0.025 (-1.42%)

CBIO Catalyst Biosciences
$1.74 /

-0.025 (-1.42%)

Options
Largest borrow rate increases among liquid names » 08:45
07/25/22
07/25
08:45
07/25/22
08:45
BOXD

Boxed

$1.97 /

-0.33 (-14.35%)

, MVIS

MicroVision

$4.81 /

-0.32 (-6.24%)

, SBLK

Star Bulk Carriers

$25.44 /

-0.955 (-3.62%)

, EVFM

Evofem

/

+

, SIRI

Sirius XM

$6.47 /

-0.065 (-1.00%)

, CBIO

Catalyst Biosciences

$1.74 /

-0.02 (-1.14%)

, GRWG

GrowGeneration

$4.94 /

-0.295 (-5.64%)

, CPRI

Capri Holdings

$47.73 /

-0.72 (-1.49%)

, CMG

Chipotle

$1,347.29 /

-22.71 (-1.66%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Boxed (BOXD) 68.35% +1.72, Microvision (MVIS) 25.89% +0.79, ProShares VIX Short Term Futures (VIXY) 12.19% +0.72, Star Bulk Carriers (SBLK) 1.30% +0.30, Evofem Biosciences (EVFM) 126.29% +0.30, Sirius XM (SIRI) 16.09% +0.23, Catalyst Biosciences (CBIO) 13.91% +0.22, Growgeneration (GRWG) 1.17% +0.21, Capri Holdings (CPRI) 0.43% +0.18, and Chipotle (CMG) 0.41% +0.15.

ShowHide Related Items >><<
SIRI Sirius XM
$6.47 /

-0.065 (-1.00%)

SBLK Star Bulk Carriers
$25.44 /

-0.955 (-3.62%)

MVIS MicroVision
$4.81 /

-0.32 (-6.24%)

GRWG GrowGeneration
$4.94 /

-0.295 (-5.64%)

EVFM Evofem
/

+

CPRI Capri Holdings
$47.73 /

-0.72 (-1.49%)

CMG Chipotle
$1,347.29 /

-22.71 (-1.66%)

CBIO Catalyst Biosciences
$1.74 /

-0.02 (-1.14%)

BOXD Boxed
$1.97 /

-0.33 (-14.35%)

BOXD Boxed
$1.97 /

-0.33 (-14.35%)

07/13/22 Wells Fargo
Boxed initiated with an Overweight at Wells Fargo
05/23/22 Citi
Boxed price target lowered to $12 from $13 at Citi
04/19/22 Citi
Boxed initiated with a Buy at Citi
01/04/22 BTIG
Boxed initiated with a Neutral at BTIG
MVIS MicroVision
$4.81 /

-0.32 (-6.24%)

03/07/22 Cantor Fitzgerald
MicroVision initiated with a Neutral at Cantor Fitzgerald
SBLK Star Bulk Carriers
$25.44 /

-0.955 (-3.62%)

07/20/22 Jefferies
Star Bulk Carriers initiated with a Buy at Jefferies
07/19/22 Stifel
Star Bulk Carriers price target lowered to $32 from $37 at Stifel
04/27/22 Jefferies
Star Bulk Carriers reinstated with a Buy at Jefferies
02/23/22 Pareto
Star Bulk Carriers downgraded to Hold from Buy at Pareto
EVFM Evofem
/

+

06/02/22 Laidlaw
Evofem initiated with a Buy at Laidlaw
05/25/22 Piper Sandler
Evofem price target lowered to $2 from $30 at Piper Sandler
01/12/22 Stifel
Restrictions on Evofem's Phexxi to ease with federal guidelines, says Stifel
11/16/21 H.C. Wainwright
Evofem price target lowered to $2 from $2.50 at H.C. Wainwright
SIRI Sirius XM
$6.47 /

-0.065 (-1.00%)

07/07/22 Citi
Sirius XM price target lowered to $7.50 from $7.60 at Citi
04/19/22 Rosenblatt
Sirius XM initiated with a Buy at Rosenblatt
04/19/22 Rosenblatt
Liberty Sirius XM initiated with a Buy at Rosenblatt
04/18/22 Morgan Stanley
Sirius XM downgraded to Underweight at Morgan Stanley amid auto headwinds
CBIO Catalyst Biosciences
$1.74 /

-0.02 (-1.14%)

05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
03/31/22 Piper Sandler
Piper says 'stick it out' with Catalyst Biosciences exploring options
11/12/21 JonesTrading
Catalyst Biosciences downgraded to Hold from Buy at JonesTrading
11/12/21 Piper Sandler
Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler
GRWG GrowGeneration
$4.94 /

-0.295 (-5.64%)

05/12/22 Oppenheimer
GrowGeneration price target lowered to $15 from $50 at Oppenheimer
05/11/22 Wells Fargo
GrowGeneration price target lowered to $4 from $8 at Wells Fargo
05/11/22 Alliance Global Partners
GrowGeneration price target lowered to $7 from $14 at Alliance Global
03/03/22 Roth Capital
Roth Capital downgrades GrowGeneration to Neutral, lowers price target to $8
CPRI Capri Holdings
$47.73 /

-0.72 (-1.49%)

07/21/22 Credit Suisse
Capri Holdings price target lowered to $56 from $65 at Credit Suisse
07/21/22 Goldman Sachs
Capri Holdings price target lowered to $59 from $69 at Goldman Sachs
07/15/22 UBS
Capri Holdings price target lowered to $65 from $91 at UBS
07/07/22 Wells Fargo
Capri Holdings price target lowered to $70 from $85 at Wells Fargo
CMG Chipotle
$1,347.29 /

-22.71 (-1.66%)

07/25/22 Stifel
Chipotle price target lowered to $1,550 from $1,850 at Stifel
07/19/22 Raymond James
Chipotle price target lowered to $1,700 from $1,850 at Raymond James
07/19/22 Credit Suisse
Chipotle price target lowered to $2,000 from $2,200 at Credit Suisse
07/19/22 UBS
Chipotle price target lowered to $1,900 from $2,100 at UBS
SIRI Sirius XM
$6.47 /

-0.065 (-1.00%)

SBLK Star Bulk Carriers
$25.44 /

-0.955 (-3.62%)

GRWG GrowGeneration
$4.94 /

-0.295 (-5.64%)

EVFM Evofem
/

+

CPRI Capri Holdings
$47.73 /

-0.72 (-1.49%)

CMG Chipotle
$1,347.29 /

-22.71 (-1.66%)

CBIO Catalyst Biosciences
$1.74 /

-0.02 (-1.14%)

CMG Chipotle
$1,347.29 /

-22.71 (-1.66%)

SIRI Sirius XM
$6.47 /

-0.065 (-1.00%)

SBLK Star Bulk Carriers
$25.44 /

-0.955 (-3.62%)

GRWG GrowGeneration
$4.94 /

-0.295 (-5.64%)

CPRI Capri Holdings
$47.73 /

-0.72 (-1.49%)

CMG Chipotle
$1,347.29 /

-22.71 (-1.66%)

CBIO Catalyst Biosciences
$1.74 /

-0.02 (-1.14%)

BOXD Boxed
$1.97 /

-0.33 (-14.35%)

SIRI Sirius XM
$6.47 /

-0.065 (-1.00%)

SBLK Star Bulk Carriers
$25.44 /

-0.955 (-3.62%)

MVIS MicroVision
$4.81 /

-0.32 (-6.24%)

GRWG GrowGeneration
$4.94 /

-0.295 (-5.64%)

EVFM Evofem
/

+

CPRI Capri Holdings
$47.73 /

-0.72 (-1.49%)

CMG Chipotle
$1,347.29 /

-22.71 (-1.66%)

CBIO Catalyst Biosciences
$1.74 /

-0.02 (-1.14%)

BOXD Boxed
$1.97 /

-0.33 (-14.35%)

Hot Stocks
JDS1 urges Catalyst stockholders to vote for director nominees » 12:26
07/22/22
07/22
12:26
07/22/22
12:26
CBIO

Catalyst Biosciences

$1.76 /

+ (+0.00%)

JDS1 announced that it…

JDS1 announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission and sent a letter to its fellow stockholders. The letter read in part, "We, together with the other participants in our solicitation, own approximately 7.6% of Catalyst's outstanding common stock, making us one of Catalyst's largest stockholders. As a fellow Catalyst stockholder, we are seeking your support and asking you to vote TODAY by signing, dating, and returning the enclosed GOLD proxy card in the postage-paid envelope provided and vote FOR ALL of JDS1's highly qualified and very experienced nominees - Shelly Lombard, Matthew Stecker, and Igor Volshteyn. You may also vote by phone or Internet by following the instructions on the enclosed GOLD proxy card...Contrary to Catalyst's protestations, our agenda is in pursuing this proxy contest is very clear. We are pursuing this proxy contest principally to ensure that the Board takes timely, if not immediate, action to distribute the maximum amount of its available cash to stockholders, including following through on Catalyst's non-committal public statement, made in apparent response to our proxy contest, that it intends to, at some unspecified point in time, return "as much as" $65 million in cash to stockholders, with the total amount to be distributed dependent upon "several factors." To be clear, Catalyst has never publicly committed to a minimum amount of cash it intends to distribute to stockholders. Nor has Catalyst ever publicly committed to a specific timetable for making any cash distributions to stockholders other than "as soon as practicable." We have no interest in controlling Catalyst and we are not even the largest stockholder. Our nominee slate is what may be referred to as a "minority slate" since, if elected, our nominees will be three directors on a Board with eight directors. Although our nominees would only constitute a minority on the Catalyst Board if elected, we believe they will bring a critical stockholder-oriented mindset and a sense of urgency to the need to unlock stockholder value by distributing to ALL stockholders the maximum amount of Catalyst's available cash and cash equivalents, save for whatever Catalyst needs to retain to provide for contingent liabilities and administrative expenses. The three highly qualified individuals we have nominated are extremely capable and ready to serve the best interests of ALL Catalyst's stockholders. We believe our nominees will bring much needed financial and other expertise to the Catalyst Board."

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$1.76 /

+ (+0.00%)

CBIO Catalyst Biosciences
$1.76 /

+ (+0.00%)

05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
03/31/22 Piper Sandler
Piper says 'stick it out' with Catalyst Biosciences exploring options
11/12/21 JonesTrading
Catalyst Biosciences downgraded to Hold from Buy at JonesTrading
11/12/21 Piper Sandler
Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler
CBIO Catalyst Biosciences
$1.76 /

+ (+0.00%)

CBIO Catalyst Biosciences
$1.76 /

+ (+0.00%)

CBIO Catalyst Biosciences
$1.76 /

+ (+0.00%)

Hot Stocks
Catalyst Biosciences sends letter to stockholders » 08:11
07/19/22
07/19
08:11
07/19/22
08:11
CBIO

Catalyst Biosciences

$1.78 /

+0.03 (+1.71%)

Catalyst Biosciences…

Catalyst Biosciences announced that it mailed a letter to its stockholders in connection with the Company's upcoming 2022 Annual Meeting of Stockholders, scheduled to be held on August 15, 2022. Catalyst's Board of Directors, following extensive engagement with the Company's largest stockholders, developed a plan to return all of the Company's available cash expeditiously to stockholders, after reserving for liabilities and obligations. "We estimate that we will ultimately be able to provide stockholders with as much as $65 million in cash, in one or more distributions, and we continue to pursue the monetization of our remaining assets and are hopeful we can generate additional cash to distribute," the company said. "Regrettably, a stockholder, JDS1, who has a history of gaining control, or trying to gain control of, cash-rich companies for its own benefit, is impeding the Cash Distribution Plan. JDS1 is seeking to replace three Catalyst directors at this year's Annual Meeting with three of its close associates who have longstanding connections to Julian Singer, JDS1's principal, and his family. Two of those three JDS1 candidates are CEOs of public companies that have signed management contracts with JDS1 and pay JDS1 substantial fees to manage their assets and cash. If it is successful at this year's Annual Meeting, JDS1 will have influenced the appointment of four of Catalyst's seven independent directors - a majority of the Company's independent board members," the company added. Catalyst urges stockholders to support the Cash Distribution Plan by reelecting the Company's nominees, by voting "FOR" ALL nominees on the WHITE proxy card

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$1.78 /

+0.03 (+1.71%)

CBIO Catalyst Biosciences
$1.78 /

+0.03 (+1.71%)

05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
03/31/22 Piper Sandler
Piper says 'stick it out' with Catalyst Biosciences exploring options
11/12/21 JonesTrading
Catalyst Biosciences downgraded to Hold from Buy at JonesTrading
11/12/21 Piper Sandler
Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler
CBIO Catalyst Biosciences
$1.78 /

+0.03 (+1.71%)

CBIO Catalyst Biosciences
$1.78 /

+0.03 (+1.71%)

CBIO Catalyst Biosciences
$1.78 /

+0.03 (+1.71%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.